These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 29391350)

  • 1. Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (
    Tang SW; Thomas A; Murai J; Trepel JB; Bates SE; Rajapakse VN; Pommier Y
    Clin Cancer Res; 2018 Apr; 24(8):1944-1953. PubMed ID: 29391350
    [No Abstract]   [Full Text] [Related]  

  • 2. Epigenetic suppression of SLFN11 in germinal center B-cells during B-cell development.
    Moribe F; Nishikori M; Takashima T; Taniyama D; Onishi N; Arima H; Sasanuma H; Akagawa R; Elloumi F; Takeda S; Pommier Y; Morii E; Takaori-Kondo A; Murai J
    PLoS One; 2021; 16(1):e0237554. PubMed ID: 33513156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies.
    Murai J; Thomas A; Miettinen M; Pommier Y
    Pharmacol Ther; 2019 Sep; 201():94-102. PubMed ID: 31128155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents.
    Zoppoli G; Regairaz M; Leo E; Reinhold WC; Varma S; Ballestrero A; Doroshow JH; Pommier Y
    Proc Natl Acad Sci U S A; 2012 Sep; 109(37):15030-5. PubMed ID: 22927417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs.
    Nogales V; Reinhold WC; Varma S; Martinez-Cardus A; Moutinho C; Moran S; Heyn H; Sebio A; Barnadas A; Pommier Y; Esteller M
    Oncotarget; 2016 Jan; 7(3):3084-97. PubMed ID: 26625211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FK228 potentiates topotecan activity against small cell lung cancer cells via induction of SLFN11.
    Yin YP; Ma LY; Cao GZ; Hua JH; Lv XT; Lin WC
    Acta Pharmacol Sin; 2022 Aug; 43(8):2119-2127. PubMed ID: 34893686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SLFN11 and ATR as targets for overcoming cisplatin resistance in ovarian cancer cells.
    König P; Eichhorn JM; Suparman E; Bückreiß N; Cinatl J; Michaelis M; Bendas G
    Biochim Biophys Acta Mol Basis Dis; 2024 Dec; 1870(8):167448. PubMed ID: 39117290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical analysis of SLFN11 expression uncovers potential non-responders to DNA-damaging agents overlooked by tissue RNA-seq.
    Takashima T; Sakamoto N; Murai J; Taniyama D; Honma R; Ukai S; Maruyama R; Kuraoka K; Rajapakse VN; Pommier Y; Yasui W
    Virchows Arch; 2021 Mar; 478(3):569-579. PubMed ID: 32474729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Schlafen-11 sensitizes colorectal carcinoma cells to irinotecan.
    Tian L; Song S; Liu X; Wang Y; Xu X; Hu Y; Xu J
    Anticancer Drugs; 2014 Nov; 25(10):1175-81. PubMed ID: 25089570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.
    Tang SW; Bilke S; Cao L; Murai J; Sousa FG; Yamade M; Rajapakse V; Varma S; Helman LJ; Khan J; Meltzer PS; Pommier Y
    Clin Cancer Res; 2015 Sep; 21(18):4184-93. PubMed ID: 25779942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers.
    Zhang B; Ramkumar K; Cardnell RJ; Gay CM; Stewart CA; Wang WL; Fujimoto J; Wistuba II; Byers LA
    Br J Cancer; 2021 Nov; 125(10):1333-1340. PubMed ID: 34294893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.
    Murai J; Feng Y; Yu GK; Ru Y; Tang SW; Shen Y; Pommier Y
    Oncotarget; 2016 Nov; 7(47):76534-76550. PubMed ID: 27708213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression.
    Luszczek W; Cheriyath V; Mekhail TM; Borden EC
    Mol Cancer Ther; 2010 Aug; 9(8):2309-21. PubMed ID: 20682643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA damage-induced cell death relies on SLFN11-dependent cleavage of distinct type II tRNAs.
    Li M; Kao E; Malone D; Gao X; Wang JYJ; David M
    Nat Struct Mol Biol; 2018 Nov; 25(11):1047-1058. PubMed ID: 30374083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy.
    Shee K; Wells JD; Jiang A; Miller TW
    PLoS One; 2019; 14(11):e0224267. PubMed ID: 31682620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum-based chemotherapy.
    Taniyama D; Sakamoto N; Takashima T; Takeda M; Pham QT; Ukai S; Maruyama R; Harada K; Babasaki T; Sekino Y; Hayashi T; Sentani K; Pommier Y; Murai J; Yasui W
    Cancer Sci; 2022 Feb; 113(2):784-795. PubMed ID: 34808009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy.
    Valdez BC; Li Y; Murray D; Brammer JE; Liu Y; Hosing C; Nieto Y; Champlin RE; Andersson BS
    Oncotarget; 2016 Sep; 7(39):63829-63838. PubMed ID: 27564097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDAC inhibitors downregulate MRP2 expression in multidrug resistant cancer cells: implication for chemosensitization.
    Kim H; Kim SN; Park YS; Kim NH; Han JW; Lee HY; Kim YK
    Int J Oncol; 2011 Mar; 38(3):807-12. PubMed ID: 21170509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic upregulation of Schlafen11 renders 
WNT- and SHH-activated medulloblastomas sensitive to cisplatin.
    Nakata S; Murai J; Okada M; Takahashi H; Findlay TH; Malebranche K; Parthasarathy A; Miyashita S; Gabdulkhaev R; Benkimoun I; Druillennec S; Chabi S; Hawkins E; Miyahara H; Tateishi K; Yamashita S; Yamada S; Saito T; On J; Watanabe J; Tsukamoto Y; Yoshimura J; Oishi M; Nakano T; Imamura M; Imai C; Yamamoto T; Takeshima H; Sasaki AT; Rodriguez FJ; Nobusawa S; Varlet P; Pouponnot C; Osuka S; Pommier Y; Kakita A; Fujii Y; Raabe EH; Eberhart CG; Natsumeda M
    Neuro Oncol; 2023 May; 25(5):899-912. PubMed ID: 36273330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Schlafen 11 predicts response to platinum-based chemotherapy in gastric cancers.
    Takashima T; Taniyama D; Sakamoto N; Yasumoto M; Asai R; Hattori T; Honma R; Thang PQ; Ukai S; Maruyama R; Harada K; Kuraoka K; Tanabe K; Sasaki AT; Ohdan H; Morii E; Murai J; Yasui W
    Br J Cancer; 2021 Jul; 125(1):65-77. PubMed ID: 33785877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.